



ALK Inhibitors U.S. Market




*1 Alecensa Rx = 227 capsules; 1 Xalkori Rx = 56 capsules; 1 Zykadia Rx = 90 capsules

ALK Inhibitors Monthly U.S. Rx*			
Month Ended:			
Drug	July (7/31/2019)	August (8/31/2019)	September (9/30/2019)
Alecensa (Roche)	1,953	1,888	1,799
Xalkori (Pfizer)	1,368	1,186	1,149
Zykadia (Novartis)	108	99	108
Total	3,429	3,173	3,056

Drug	Annualized Rx* (Based on Trailing 1 Month)	% of Rx*
Alecensa (Roche)	21,593	59%
Xalkori (Pfizer)	13,783	38%
Zykadia (Novartis)	1,294	4%
Total	36,670	100%



*1 Alecensa Rx = 227 capsules; 1 Xalkori Rx = 56 capsules; 1 Zykadia Rx = 90 capsules



Drug	Annualized WAC Sales (Based on Trailing 1 Month)	% of WAC Sales	Est. Annualized Net Sales
Alecensa (Roche)	\$ 305,618,263	57%	\$ 296,744,571
Xalkori (Pfizer)	\$ 215,082,019	40%	\$ 138,958,602
Zykadia (Novartis)	\$ 13,659,097	3%	N/A
Total	\$ 534,359,379	100%	\$ 435,703,173

Drug	TTM WAC Sales (TTM Ended 09/30/2019)	% of WAC Sales
Alecensa (Roche)	\$ 306,293,292	55%
Xalkori (Pfizer)	\$ 233,719,859	42%
Zykadia (Novartis)	\$ 15,351,601	3%
Total	\$ 555,364,752	100%

Drug	Reported U.S. Net Sales (TTM Ended 09/30/2019)	Net to WAC
Alecensa (Roche)	\$ 297,400,000 ¹	97%
Xalkori (Pfizer)	\$ 151,000,000	65%
Zykadia (Novartis)	U.S. sales not reported	N/A
Total	\$ 448,400,000	

¹Reported sales were converted from CHF to USD using average exchange rates of the applicable periods